RxDoctor Payments Data

Rodney Siau

Family · Albany, GANPI 1639216344

Payments from drug & device makers

$12,949in general payments, 2019–2025

Across 444 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$3K
  • Medtronic$2K
  • Sumitomo Pharma America, Inc.$968
  • Pfizer$750
  • Bayer$671
  • Astellas Pharma US Inc$585
  • plus $5K from 30 others

What the payments were for

  • Travel & lodging$1,33710%
  • Food & beverage$11,52389%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,949 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$22,053
Medicare patients
169
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$278,930
OrgovyxRelugolix76$201,220
GemtesaVibegron149$103,929
MyrbetriqMirabegron86$64,795
Tamsulosin Hcl786$11,326
Finasteride705$7,348
Fosfomycin Tromethamine28$4,477
Silodosin51$3,572
Testosterone27$3,325
Testosterone Cypionate79$2,014
Tadalafil41$1,757
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$1,441
Dutasteride44$1,247
Oxybutynin Chloride ErOxybutynin Chloride58$968
Levofloxacin196$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$585$343,725106 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$968$305,149225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →